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a  b  s  t  r  a  c  t
Formulation  development  presents  signiﬁcant  challenges  with  respect  to  protein  therapeutics.  One  com-
ponent  of these  challenges  is to  attain  high  protein  solubility  (>50  mg/ml  for  immunoglobulins)  with
minimal  aggregation.  Protein–protein  interactions  contribute  to aggregation  and  the  integral  sum  of
these  interactions  can  be quantiﬁed  by a thermodynamic  parameter  known  as  the  osmotic  second  virial
coefﬁcient  (B-value).  The  method  presented  here utilizes  high-throughput  measurement  of  B-values  to
identify  the  inﬂuence  of additives  on  protein–protein  interactions.  The  experiment  design  uses  three
tiers  of  screens  to arrive  at ﬁnal  solution  conditions  that  improve  protein  solubility.  The  ﬁrst  screen  iden-
tiﬁes  individual  additives  that  reduce  protein  interactions.  A  second  set  of B-values  are  then  measured
for  different  combinations  of these  additives  via  an  incomplete  factorial  screen.  Results  from  the incom-
plete  factorial  screen  are  used  to  train  an  artiﬁcial  neural  network  (ANN).  The  “trained”  ANN  enableseural network
esign of experiments
predictions  of B-values  for  more  than  4000  formulations  that include  additive combinations  not  previ-
ously  experimentally  measured.  Validation  steps  are  incorporated  throughout  the  screening  process  to
ensure  that  (1) the protein’s  thermal  and aggregation  stability  characteristics  are  not  reduced  and  (2)  the
artiﬁcial  neural  network  predictive  model  is accurate.  The  ability  of  this  approach  to  reduce  aggregation
and  increase  solubility  is  demonstrated  using an IgG protein  supplied  by  Minerva  Biotechnologies,  Inc.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Protein therapeutics is the fastest growing class of drugs in the
harmaceutical industry [1]. As basic research reveals biological
athways, protein deﬁciencies/abnormalities and key protein tar-
ets involved in disease states, we gain a greater understanding
f how protein molecules can be used to inﬂuence those diseases.
he ﬁrst clinically demonstrated example of a protein therapeu-
ic involved replacement of human insulin for diabetes treatment
2]. Even in those cases that do not involve direct protein replace-
ent, engineered immunoglobulins or other proteins have been
emonstrated to inﬂuence disease pathways [3].
To achieve an effective protein dose using a small injection
olume, the concentration of clinically approved protein drugs
Abbreviations: ANN, artiﬁcial neural network; BCA, bicinchoninic acid; DLS,
ynamic light scattering; Fab, antibody fragment region; FDA, food and drug
dministration; GLM, general linear model; HSC, high-throughput self-interaction
hromatography; IgG, immunoglobulin G; Mab, monoclonal antibody; MES, 2-(N-
orpholino) ethanesulfonic; PBS, phosphate buffered saline; Rh, hydrodynamic
adius; RMSE, root mean square error.
∗ Corresponding author. Tel.: +1 205 934 5329; fax: +1 205 934 2659.
E-mail addresses: delucas@cbse.uab.edu, duke2@uab.edu (L.J. DeLucas).
ttp://dx.doi.org/10.1016/j.jchromb.2014.09.003
570-0232/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
typically exceeds 100 mg/ml  [4]. Physical stability of the protein
at these high concentrations is a critical concern due to poten-
tial for an immune response to protein aggregates [5]. Therefore,
solubility and physical stability are key variables that must be
addressed when developing a protein therapeutic. The Interna-
tional Conference on Harmonization (ICH), whose objective is to
harmonize requirements for safety, effectiveness and quality for
pharmaceutical products, includes molecular characterization as
one factor of a stability indicating proﬁle [6]. To maintain phys-
ical stability at high concentration, a large number of different
formulations must be evaluated followed by additional optimiza-
tion of promising candidates—a process that may  require several
months, consuming signiﬁcant quantities of protein. A process is
needed to efﬁciently evaluate solubility behavior of protein drug
formulations. The following presents a general method to improve
protein colloidal stability of protein solutions based on a novel high-
throughput HPLC system and a sequential design of experiments
(DOE) that provides rational screening of formulations (beginning
with individual buffered additives and progressing to complex
formulations).
Evaluation techniques used to determine protein solubility
behavior can be grouped into two broad categories; (1) detection of
aggregates and (2) measurement of protein–protein interactions.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Experiment ﬂow. Flow chart of the experiments conducted to identify formu-00 D.H. Johnson et al. / J. Chr
xamples of aggregate detection methods include size-exclusion
hromatography, analytical ultracentrifugation and dynamic light
cattering (DLS). The integral sum of protein–protein interactions
as opposed to site-speciﬁc interactions) is typically quantiﬁed by
 thermodynamic parameter known as the osmotic second virial
oefﬁcient (also referred to as the B value) [7–10]. The B parameter
s correlated with both protein solubility [11–13] and the ability
f a protein to crystallize [11,13–15,15–17] depending on whether
he protein–protein interactions are repulsive (positive B values)
r attractive (negative B values), respectively. Several methods
xist to measure B values, including osmotic pressure [18], ana-
ytical ultracentrifugation [19], static light scattering [14,20] and
elf-interaction chromatography [8] (SIC).
We  previously described the development process of a novel,
igh-throughput instrument that uses an established technique,
elf-interaction chromatography (SIC) to rapidly measure B-values
8,9,21,22]. SIC requires that the protein of interest is randomly
ound to column media (static phase) while the column is equil-
brated with the formulation being tested. A small bolus of
rotein (1 l) is injected onto the column and its elution vol-
me/time measured by UV absorption. The volume required to
lute the protein of interest from the column is related to the
rotein–protein interactions of the injected bolus of protein with
andomly oriented stationary protein. Other variables affecting B-
alue calculations such as the concentration of bound protein and
onspeciﬁc protein–media interactions are discussed in the meth-
ds section. The initial protein-media binding step requires up to
 mg of puriﬁed protein with each experimental B-value measure-
ent in different test formulations consuming an additional 1 g of
rotein. The time required for each measurement is approximately
wo hours (∼30–45 min  for protein elution and an additional hour
or re-equilibration in a new formulation condition). The advan-
ages of SIC over other methods to calculate B-values include: (1)
elatively straightforward, automatable experimental protocol that
oes not require speciﬁc operator expertise/experience, (2) low
otal protein consumption, (3) dead column reference and multiple
 value measurements per run, (4) ability to use the technology for
oth aqueous and membrane proteins.
In addition to inherent beneﬁts of SIC, the high-throughput
elf-interaction chromatography (HSC) system includes several key
echnological improvements including: (1) simultaneous use of
our columns, (2) miniaturization of column dimensions result-
ng in a signiﬁcant reduction in total protein consumption, (3) a
igh capacity formulation reservoir with automated robotic dis-
ensing of different formulation conditions, (4) automated data
cquisition. This lab previously reported the hazard analysis pro-
ess which was used in the development of the HSC [23]. Use of the
SC instrument is combined with an approach that includes multi-
le levels of formulation screens and validation steps to assess: (a)
dditive inﬂuence on protein thermal stability, (b) protein–protein
nteractions and (c) identify formulations with improved solubility.
. Material and methods
.1. Multi level additive screen
The novel approach described in this paper provides a rapid, cost
ffective method to determine solution conditions that optimize
rotein solubility. It requires 10–30 mg  of protein and two to six
eeks depending on the number of conditions needed to optimize
olubility. The approach includes multiple levels of high throughput
creening along with validation steps at each stage of the process.
he overall goal of the approach is to determine which combi-
ation and concentration of additives minimize protein–protein
ttraction, thereby increasing protein solubility.lations with reduced aggregation. Most steps are followed by two  actions: validation
and comparison with baseline and the next experiment in the screening process.
In the ﬁrst stage, additives are screened individually via exper-
imentally measured B-values to identify those most effective at
reducing protein–protein interactions. More than 300 additives are
approved by the FDA for use in injectable drug formulations as
inactive ingredients [24]. If all 300 were to be assessed, just three
concentration levels of two additives at three pH levels would result
in over 1.2 million possible formulation conditions. Even with high-
throughput hardware the physical evaluation of this number of
formulations is infeasible. The initial screen measures B values of
the protein in each formulation consisting of the storage formula-
tion along with one additional additive. This initial screen permits
rank ordering of the individual additives with respect to their indi-
vidual effect on the protein under study. This is an important new
addition to the screening process and allows for the selection of not
only additives known to improve general protein stability, but also
those which may  be more speciﬁc to the protein of interest.
The individual additives identiﬁed as producing the most pos-
itive B values in the initial screen are combined in the incomplete
factorial screen using an orthogonal array (assuring combinations
of additives are equally represented throughout the screen). These
more complex formulations are based on a balanced combination
of additives at different concentrations. For each protein stud-
ied a numerical model of how additives affect protein–protein
interaction (B-value) is created by training an artiﬁcial neural
network (ANN) using experimental data generated from the bal-
anced screen. The neural network model is used to predict the
B-value of the full factorial of screened additives. The following
experimental results demonstrate the ability of an HSC system
combined with this multi-tiered screening process to rapidly deter-
mine formulations with signiﬁcantly improved solubility behavior
for a candidate IgG protein therapeutic compared to its original
formulation.
The ﬂow chart presented in Fig. 1 shows that the entire for-
mulation screen is performed in ﬁve distinct phases: baseline
measurements, initial screen, incomplete factorial screen, neural
network modeling and conﬁrmation with integrated quality con-
trol steps. Expanded baseline measurements include SIC as well
as DSC and DLS. These measurements are referenced through-
out the screening process to identify false positive B values. Each
step is described in more detail in the following sections, begin-
ning with the HSC instrument that enables automated parallel data
collection.
2.2. High-throughput self-interaction chromatography (HSC)
HSC requires covalent attachment of the protein of inter-
est (∼2 mg)  to media contained in a chromatography column.
The same protein is injected into the mobile phase and reten-
tion times measured. Protein retention time measurement in
each formulation requires approximately 1 g of additional pro-
tein per column. Each experiment requires approximately two
hours using traditional column sizes and a precision HPLC.
To reduce experiment time and protein consumption com-
pared to traditional B measurement techniques, this laboratory
reduced column dimensions (0.5 mm × 180 mm)  and developed an
D.H. Johnson et al. / J. Chromato
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Cig. 2. Schematic drawing of the HSC system. For clarity, this ﬁgure shows only a
ingle ﬂow path. The valves, platform and detectors handle four channels in parallel.
utomated high-throughput screening system to enable uninter-
upted, simultaneous data acquisition from four chromatographic
olumns.
A schematic drawing of the HSC system is shown in Fig. 2.
our valves control ﬂuid ﬂow throughout the system including
he formulation, injection, and bypass valves. The formulation
alve controls access of the formulation pump to the reservoir or
ther portions of the system. This pump withdraws formulations
rom the reservoir to the formulation syringe which then extrudes
hese solutions over one of the four columns. Bypass valves enable
ushing the entire system with new formulations. This process is
ully automated, accommodating 48 different formulations in 10 ml
eservoirs. After column equilibration with new formulations, the
rotein is automatically injected over each column via the injection
alve. The retention time of the eluted protein is determined using
 UV280 detector.
.2.1. Baseline measurements
Protein purity is initially conﬁrmed via SDS PAGE and stain-
ng with BioSafe Coomassie. Protein B-value measurements are
stablished using a “reference buffer” solution which provides a
aseline reference for subsequent comparisons to identify formu-
ation improvements. The reference buffer is typically a previously
dentiﬁed “good formulation” solution, judged by the extent of non-
peciﬁc protein aggregation using size exclusion chromatography
SEC) and/or dynamic light scattering (DLS). To ensure confor-
ational consistency of the protein, the unfolding temperature
s measured using a MicroCal VP-capillary differential scanning
able 1
hromatography media binding test.
Binding group Binding pH Reagents 
Formyl –NH2 6.9–9.0 NaBH3CN 
Tresyl  –NH2, –SH 7.0–9.0 None 
Amino  –HOOC, –OHC 4.5–6.0 EDCa/NHSb
Carboxy –NH 4.5–6.0 EDCa/NHSb
a Ethyl(dimethylaminopropyl) carbodiimide.
b n-Hydroxysuccinimide.
c 3-Hydroxypropionic acid.gr. B 971 (2014) 99–106 101
calorimetry system. The B-value for the protein in the reference
buffer can be measured via SIC using either a Shimadzu HPLC or
the custom HSC system. This B-value measurement is the primary
metric by which additives and formulations are evaluated. Base-
line measurements are repeated between screens to ensure that
the integrity of the column is not adversely affected due to changes
in capacity (due to irreversible protein binding) and degradation
of the media and/or media packing (caused by excessive back-
pressure, non-speciﬁc irreversible protein binding). The reference
buffer for the Fab protein presented in this paper is phosphate
buffered saline (PBS—diluted 1× contains 137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4).
2.3. Self interaction chromatography
From a broad perspective, self-interaction chromatography is
an afﬁnity chromatography technique that involves binding the
protein of interest to chromatography media, injecting a bolus of
protein over the column, and measuring the retention time of the
protein as it passes through and interacts with the protein bound
to the media. Longer retention times are associated with increased
protein–protein interaction [7,22]. The following sections provide
a detailed description of the SIC method including media selec-
tion (based on evaluation of the concentration of bound protein),
column preparation, retention time measurement and B-value cal-
culation based on protein retention time.
2.3.1. Binding test
There are multiple protein binding chemistries available to
covalently bind protein to media such that the point of attach-
ment between the protein’s surface and the media is random (this
is accomplished by using free amine or carboxyl functional R-
groups associated with amino acids). To identify optimal binding
conditions, four different chemistries available from TosoHaas are
considered: formyl, tresyl, amino and carboxy. For each media type,
20 l of beads are washed three times with 1 ml  of the appropriate
binding buffer for the given media (MES or phosphate buffer at pH
6.0 or 8.0 depending on the media). The binding tests are performed
by adding 20 l of 5 mg/ml  protein to each sample of washed beads.
Reagents are added according to the given chemistry. Table 1 dis-
plays the media options tested, their binding formulations, reagents
required and binding times. After the binding process is com-
plete, the media, now bound with some quantity of protein, is
washed again three times with 200 l of the binding buffer. A BCA
assay is performed on each media sample to precisely quantify the
amount of bound protein. This process requires ∼0.4 mg of pro-
tein (20 l × 5 mg/ml  × 4 tests). In addition to identifying the media
with the highest binding capacity, DSC is performed on the pro-
tein in the binding buffer, as a quality control step, to conﬁrm that
the binding buffer does not destabilize or partially denature the
protein. The binding chemistry with the highest quantity of bound
protein, as determined by the BCA assay, is used for subsequent
preparation of the SIC columns.
Binding time Blocking Blocking time
4 h Ethanolamine 1 h
24 h Ethanolamine 4 h
24 h 3HPc 4 h
24 h Ethanolamine 4 h
1 omato
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.3.2. Binding and packing a column
For each protein investigated, the protein chemical binding pro-
ess is scaled up 15-fold to support simultaneous use of three “live”
olumns (“live” column = column with protein). A fourth “dead” col-
mn (“dead” = column without protein) is prepared to serve as a
ontrol to assess protein–media interactions. The binding process
or the live columns consists of adding 300 l of 5 mg/ml protein
o 300 l of media. The appropriate reagents are added to the pro-
ein media solution followed by placement of samples on a rotating
ixer for an appropriate amount of time according to Table 1. After
ompletion of the protein binding step, the media is washed three
imes with 2 ml  of the binding buffer. Using the identical binding
eaction, remaining active sites of the media are capped with a
apping reagent (0.5 M ethanolamine or 3-hydroxypropionic acid)
sed in place of the protein solution. At this point, 100 l of media
s prepared with the capping reagent (no protein) to produce a
apped-only “dead” column media. It should be noted that the cova-
ently bound protein assures several different orientations on the
olumn media due to the fact that the protein’s covalent bond is
ormed with free amine nitrogens (which are typically available at
ultiple positions along the proteins exterior surface). Thus SIC-
etermined second virial coefﬁcients are not less due to a speciﬁc
rotein-media orientation that would prevent interaction with var-
ous regions on the protein’s surface.
The prepared media is packed into 0.02′′ i.d., 1/16′′ o.d. and 20 cm
ength columns consisting of teﬂon FEP tubing (IDEX) sealed at one
nd with a union (Valco ZU1CFPK) containing a 2 micron frit (Valco
SR1-10). Two 1 cm sections are cut from the end of each column for
rotein analysis via Pierce BCA assay to determine the protein con-
entration bound to the column media. The concentration of bound
rotein is a critical variable required to calculate B from the mea-
ured protein retention time. Generally, for a 150 kDa protein (IgG)
 minimum binding concentration of 5 mg/ml  is required to yield a
ufﬁcient number of protein interactions to provide the sensitivity
eeded to accurately measure B-values for each solution condition.
inally the packed column is sealed with a union containing a 2
icron frit.
To separate injected protein from the storage buffer in which
t is contained a desalting “guard” pre-column is also prepared for
ach live column and the dead column. This ensures the protein
s fully equilibrated in the formulation of interest before it passes
ver the SIC column. The 60 cm,  0.03′′ i.d., 1/16′′ o.d. teﬂon FEP guard
olumn uses Sephadex G-25 media. The media is prepared by soak-
ng in a phosphate buffered saline (PBS) solution, pH 7.4, for 4 h
nd rinsed 4 times with 5 ml  of PBS. The media is packed into the
olumn tubing and sealed at both ends as described for the SIC
olumns.
.3.3. Retention time measurements
A guard column is positioned prior to each live and dead col-
mn to separate absorption peaks caused by salts, buffer and other
mall molecules contained in the base buffer used to solubilize
he protein (these small molecules sometimes absorb at or close
o 280 nm and co-elute close to the protein absorption peak). The
ystem is equilibrated in the formulation of interest by passing
pproximately 5 system volumes of formulation solution through
he columns. After equilibration, a standard afﬁnity chromatogra-
hy experiment is performed by injecting the protein of interest in
he mobile phase formulation at a constant 8 l/min ﬂow rate and
rotein elution time is measured from the time of injection until
he time of elution from each column (protein elution is detected
ia U.V. absorbance at 280 nm). The retention time is deﬁned as
he time required for the protein to pass through the SIC column
nly—total elution time through both columns minus the elution
ime through the guard column, measured separately. This processgr. B 971 (2014) 99–106
is repeated for each of the additive formulations contained in the
initial and incomplete factorial screens.
2.4. DSC conﬁrmation
B-values for protein in each formulation are measured followed
by assessment of protein integrity for the nine additives yielding
the most positive B-values (this is assessed using DSC  measure-
ments of protein thermal stability). This step serves as a quality
control measure to ensure that protein denaturation is not a signif-
icant factor affecting protein retention times. Samples are prepared
for DSC by buffer exchange using a centrifugal concentrator. A
quantity of 0.25 mg  protein from solution is added to the centrifuge
tube. Three ml  of formulation is added and spun down at 3000 rpm
in an Eppendorf-5810R centrifuge to 500 l and this is repeated
four times for a buffer exchange of over 99.9%. The ﬁnal efﬂuent is
used as the blank control for the DSC experiment. If a formulation
fails the DSC conﬁrmation step (a drop in unfolding temperature
of more than 4 ◦C) the next most positive B-value formulation is
evaluated until nine additives are identiﬁed that improve B-value
without signiﬁcantly reducing protein unfolding temperature.
2.5. B value screens
2.5.1. Initial screen
The initial screen is used to identify individual additives that
contribute to protein-protein repulsion (positive B-value). The for-
mulations for the initial screen are prepared by combining 10×
concentrated phosphate buffered saline (PBS – diluted 1× contains
137 mM NaCl, 2.7 mM KCl, 10 mM Na3PO4, 2 mM KH2PO4), and a
single additive from concentrated stock, ﬁlled to 90% volume with
Millipore H2O and titrated with NaOH or HCl to pH 7.4. The list of
forty additives, each tested individually in the initial screen, can be
found in Appendix A. The B-value of the protein of interest is mea-
sured in each formulation using SIC. The additives most beneﬁcial to
reduce protein–protein interactions are not known a priori. There-
fore, the purpose of the initial screen is to identify additives that
reduce protein–protein interaction for a given protein. Thermal
stability of the protein combined with those individual additives
exhibiting the nine highest B-values is then conﬁrmed using DSC.
Three salts and six additives with the highest B-values which also
maintain thermal stability via DSC (deﬁned as those additives that
do not result in more than a negative 4 ◦C temperature shift) are
chosen for the incomplete factorial screen.
2.5.2. Incomplete factorial screen
After completion of the DSC tests, the top nine solutions are
combined in an incomplete factorial using an orthogonal array
according to the Taguchi method [25]. This method ensures that
additive identity and additive concentration are equally repre-
sented throughout the incomplete factorial screen. The screen
speciﬁes more complex formulations with multiple additive com-
ponents at high, medium and low concentrations. B-values of the
protein in each formulation of the incomplete factorial screen can
be measured by SIC using either the HSC system or a Shimadzu
HPLC.
2.5.3. Neural network training
The measured B-values are used to create a numerical model
of how speciﬁc additives in the formulation affect protein–protein
interaction. An artiﬁcial neural network (ANN) model [26] is ﬁrst
trained ﬁve separate times using a different random set of 4/5 of
the data with the remaining 1/5 of the data used for validation. The
weights of the neural network are adjusted based on the training set
using a standard back-propagation algorithm until the error of the
validation set (not used to adjust weights) is no longer improved
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y incremental changes to the ANN weights. This is an established
ethod to train and prevent over-ﬁtting of an ANN and is described
n Bishop’s book, Neural Networks for Pattern Recognition [27]. In
 previous publication [28], our lab compared this method to that
f a standard general linear model (GLM) and found the ANN to
xhibit reduced prediction error compared to the GLM.
.5.4. Neural network prediction and conﬁrmation
The trained ANN returns a B-value given a formulation where
he output is based on previously measured B-values. After training
s complete the neural network is presented with each formulation
n the complete factorial combination of all parameters measured.
his consists of over 4000 possible formulations that combine one
r two additives, a salt and a buffer. The ability of the ANN to predict
-values of novel formulations is evaluated by B-value measure-
ent (by SIC) of several predicted formulations, chosen throughout
he predicted B-value range. A root mean square error (RMSE) is
etermined for the model predictions compared to the actual B-
alues measured. Conﬁrmation measurements serve two  purposes:
n evaluation of the model predictions and conﬁrmation of pre-
icted formulations with improved B-values.
.6. Thermal stability conﬁrmation
The predicted formulations with increased B-value measure-
ents are experimentally validated followed by DSC conﬁrmation
f protein thermal stability in these new formulations.
.7. Indirect solubility testing
Dynamic light scattering (DLS) is used to indirectly test the
olution solubility characteristics of the protein by evaluation of
he aggregation properties of the protein as protein concentration
s increased. Due to a limited supply of protein (the proprietary
ab protein, provided by Minerva Biotechnologies, Inc., used for
hese experiments was of limited supply), DLS measurements were
estricted to the most positive B-value formulation (by prediction
nd measurement) and the most negative B-value formulation from
he initial screen. The rationale is to determine if more positive B-
alue predicted formulations produce signiﬁcant improvements in
olubility behavior. Each protein formulation is ﬁltered through a
.22 micron ﬁlter into a 10 l quartz 90◦ scattering cell. Scattering
ounts are measured using a Wyatt DynaPro Titan DLS system to
onﬁrm that there is not a signiﬁcant scattered light signal from the
uffer itself. The protein is buffer-exchanged into each formulation
sing centrifugal concentrators. Diffusion coefﬁcients and appar-
nt hydrodynamic radii of the protein are measured in the solution
t a ﬁxed concentration. The Fab sample is concentrated with DLS
easurements taken at various points during in the concentration
rocess. The aggregation behavior of the protein is compared as a
unction of protein concentration for each formulation. The mini-
al  use of protein required for DLS measurements and the fact that
rotein can be recovered for additional tests resulted in this being
he method of choice for comparing aggregation behavior of the
rotein.
. Calculation of B-value
The standard method of B value calculation, published by
essier, Lenhoff and Sandler [8], is used in this research:
 = NA
(
VHS −
k′ )MW2 ϕ
In this equation, NA is Avogadro’s number (molecules/mol) and
W is molecular weight (g/mol). VHS (ml/molecule) is the hard
phere volume of the protein of interest (calculated as a globulargr. B 971 (2014) 99–106 103
protein based on molecular weight). The parameter, ϕ (cm2/ml),
is the phase ratio of the media deﬁned as the ratio of the surface
area available to that of the volume available to a mobile phase pro-
tein passing through the media. Phi is a characteristic of the media
used and molecular weight of the protein and has been determined
for several media types including TosoHaas afﬁnity media [29]. The
parameter  (molecules/cm2) is the amount of protein per unit area
bound to the media (determined via the BCA assay as described
previously).
The ﬁnal parameter k′ is the retention factor. While the other
parameters are ﬁxed for a given column, the k′ measurement is
the primary variable associated with changes in protein–protein
interactions. k′ is calculated according to the following [8]:
k′ = (V − V0)
V0
V is the retention volume of the protein over the live column and
V0 is the retention volume of an equivalently sized non-interacting
marker. Previously an acetone marker has been used as the non-
interacting marker and a correction was used to adjust for the
small size of the acetone marker compared to the protein [8,9,30].
However, the addition of the guard column used to equilibrate the
protein in the mobile phase substantially shifts the acetone marker
with respect to the protein marker. In the multi-column system,
the dead column is used to identify the non-interacting retention
volume. Therefore, V0 is the retention volume of protein eluted
from the dead column in the formulation of interest. This method
has the added beneﬁt of accounting for changes in protein–media
interactions in the presence of different formulations.
4. Results
Fab protein was  subjected to the novel multi-tiered screening
process. The speciﬁc antigen is proprietary and not known to our
laboratory.
4.1. Minerva Fab-initial screen
The primary goal of the Minerva project was to produce a
highly soluble storage solution for the protein, not a solution
for direct injection. Therefore, this screen contains additives and
concentrations not approved for human use. Identifying such a for-
mulation is useful for long-term storage of protein produced on
a large scale and for preliminary formulations that can be used
with other structure–function analysis methods as well as for
in-vivo animal studies. With different initial screen components
the screening methodology and high-throughput technology are
applicable to preparation of solution conditions for pre-clinical
evaluation. Minerva provided our lab with ∼25 mg  of the Fab
portion of a proprietary monoclonal antibody (Mab) being con-
sidered for future clinical trials. It was assumed that if improved
solubility conditions could be discovered for the Fab, these con-
ditions would also exhibit improved solubility for the complete
monoclonal antibody. Components and concentrations of the addi-
tives used in this screen can be found in Appendix A.
Table 2 shows the additives producing the nine highest B-values
chosen from the initial screen. This includes the additives that
failed DSC conﬁrmation (1,6-hexanediol and Li2SO4). These two
additives were replaced with those producing the next most pos-
itive B-values, NaCl and Glutamic Acid. The additives chosen from
the initial screen are applied to an orthogonal array [31] to deter-
mine the additives and concentrations used for each formulation
condition in the incomplete factorial screen. A full list of the 36 for-
mulations in this phase of the screen can be found in Appendix B and
the most positive B-values identiﬁed in the screen are in Table 3.
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Table 2
Most positive B-values of Minerva Fab initial screen.
Additive name B-valuea measured Delta TM (◦C)
Default Buffer-PBS 0.2 +0.0
1.  0.1 M Arginine 5.8 +0.6
2.  400 mM LiCl 5.1 −1.6
3.  400 mM Na Thiocyanate 4.4 −3.7
4.  0.1 M Arg., 0.1 M Glu. Acid 3.2 NA
5.  400 mM LiSO4 1.2 −9.0
6.  0.1 M Glucose 0.8 −0.6
7.  400 mM Na Citrate 0.1 +2.5
8. 0.1 M Trehalose 0.0 −0.1
9.  10% (w/v) 1,6 Hexanediol 0.0 −10.5
10. 400 mM NH4 Citrate −0.6 −2.3
a (×10−4 mol  ml/g2).
Table 3
Most positive B-values from minerva Fab incomplete factorial screen.
Formulation B-valuea
measured
Default Buffer–PBS 0.2
1.  0.1 M Phosphate pH 7.4, 0.15 M NaCl, 0.2 M Na Citrate,
0.6 M NH4 Citrate
5.6
2. 0.1 M Phosphate pH 7.4, 0.15 M NaCl, 0.1 M Trehalose,
0.05 M Glucose
4.1
3. 0.1 M Tris pH 8.0, 0.05 M LiCl, 0.4 M Na Citrate 2.7
4.  0.1 M Phosphate pH 7.4, 0.05 M NaSCN, 0.4 M NH4
Citrate, 0.15 M Arginine
2.1
5. 0.1 M MES  pH 6.1, 0.1 M NaCl, 0.05 M Glutamic Acid,
0.15 M Trehalose
1.9
6.  0.1 M Phosphate pH 7.4, 0.05 M LiCl, 0.15 M Trehalose 1.4
7.  0.1 M Tris pH 8.0, 0.1 M NaCl, 0.1 M Trehalose, 0.15 M
Arginine
1.4
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B8.  0.1 M MES  pH 6.1, 0.15 M NaSCN, 0.1 M Glutamic Acid 1.4
a (×10−4 mol  ml/g2).
From the 27 different neural networks trained, the 5 × 2 topog-
aphy provides the smallest validation error across all validation
ets for the Minerva Fab protein. The average validation error is 1.2
 units. The trained neural network produces a range of B-value
redictions from −5.4 to 4.3 B units and 4 formulations from the
op quartile of B-values are chosen to yield improved formulations.
ifferent topologies represent a different number of variables con-
idered for inﬂuence on B-value. It is expected that some topologies
those that consider too few or too many variables) would pro-
uce lower validation errors than others. The evaluation of multiple
opologies is automated and does not require additional effort and
ccounts for the fact that the number of variables which inﬂu-
nce B-value are expected to differ from protein to protein. The
easured conﬁrmation of B-value by SIC and change in unfoldingemperature by DSC are given in Table 4.
The restriction on protein quantity received (25 mg)  limits
he maximum solubility that can be determined for a given
able 4
-value conﬁrmations and DSC unfolding temperatures for Fab.
Formulation B-valuea
predicted
B-valuea
measured
Delta
Tm (◦C)
1. 100 mM Tris pH 8.0, 100 mM NaCl,
150 mM Trehalose, 400 mM NH4
Citrate
3.4 0.8 +5.4
2.  100 mM Tris pH 8.0, 150 mM NaSCN,
100 mM Trehalose 600 mM NaCitrate
1.6 1.6 +5.0
3.  100 mM Tris pH 8.0, 150 mM LiCl,
150 mM Arg-HCl, 50 mM Glucose
1.0 0.9 +0.2
4.  100 mM Phosphate pH 7.5, 150 mM
NaCl, 100 mM Trehalose, 100 mM
Glutamic Acid
4.1 2.1 +1.9
a (×10−4 mol  ml/g2).Fig. 3. Solubility estimates of Fab from Minerva.
formulation. In the case of the Minerva Fab the formulations sub-
mitted to the company were tested by the company with larger
protein quantities. Minerva concentrated the complete monoclonal
antibody (Mab) in each formulation until visible precipitation was
observed. These results are shown in Fig. 3.
5. Discussion
Each step in the screening process is an important part of deter-
mining improved formulation conditions. The following discussion
compares the results of the protein evaluation. The following sub-
sections are focused on a single step in the screening process
outlined in Fig. 1.
5.1. Baseline
Baseline measurements are important for both quality assur-
ance (of the initial quality of the protein) and quality control (of
formulation improvements). The baseline unfolding temperature
provides a reference to quantify shift in unfolding temperature for
protein equilibrated in each formulation. In the case of denatured
protein, DSC does not result in a positive heat capacity signal and
can be used to identify formulations which denature the protein.
An additional quality assurance step includes evaluation of pro-
tein binding to a small quantity of each media type to identify the
optimum binding chemistry for a particular protein. Both proteins
bound to Tresyl media at greater than 7 mg/ml  and demonstrated
typical IgG unfolding temperatures from 60 ◦C to 90 ◦C. This ensures
that the best media is chosen for protein binding.
Regarding use of PBS (pH 7.4) as the baseline formulation, it
should be noted that proteins close to their isoelectric point are gen-
erally less soluble; a pH of 7.4 is close to the IgG isoelectric point of
8.2. In the case of the Minerva protein the simple task of reducing pH
of the buffer did not increase solubility. This protein and most other
proteins evaluated are generally “problem” proteins (proteins that
exhibit low solubility). The starting point for the formulation screen
for Minerva’s Fab was  the best available based on information pro-
vided by Minerva (the company approached Soluble Therapeutics
due to their prior difﬁculty improving the solubility of the protein).
Obviously, no single screening process can always produce and
guarantee the maximally optimal formulation. That would require
a complete factorial testing of the search space. As noted in the
introduction, even with severe limitations on the dimensionality
of the search space (2 additives, 3 concentration and pH levels) an
exhaustive search of the space is not feasible. Soluble Therapeu-
tics’ screening process is designed to improve formulations with
an approach that begins with identiﬁcation of individual additives
that inﬂuence protein–protein interactions followed by expansion
to more complex formulations that contain multiple additives and
omato
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dditive concentrations. After individual additives are selected, an
ncomplete factorial additive screen is used to improve the chance
f identifying combinations of additives that work well together.
.2. Initial screen
The initial screen of individual additives includes additives not
n the FDA database. A wide range of additives was chosen in order
o evaluate the overall system’s capability to predict B-values that
odify solubility behavior. Each additive formulation is screened
sing SIC to identify the B-value associated with the additive. Indi-
idual additives with the highest B-values from the initial screen are
dentiﬁed in Tables 2 and 5 for the Minerva Fab. Formulation opti-
ization experiments performed with proprietary proteins (both
gGs and other protein classes), using FDA-approved additives,
esulted in alternative additives and additive concentrations.
As noted earlier, PBS was both the starting point for the initial
creen and the “best” formulation available (deﬁned as the base
uffer) at the time. This is usually not the case. However, when a
ore optimally soluble formulation is available it is not necessarily
he best starting point for the initial screen. Beginning with a com-
lex formulation augmented with additives is likely to result in a
earch space located around a local maximum (but not necessarily
he global maximum). Identiﬁcation of a minimal buffer (such as
BS) allows for the inclusion of individual additives that may  have
 signiﬁcant impact on protein–protein interactions; this may  not
e distinguishable in an already complex formulation. Thus, the
inimal buffer formulation enables broadening of the search space
o include more diverse formulations for the incomplete factorial
creen.
Although some individual additives, such as trehalose, are
nown to improve thermal stability [32], the primary metric of the
SC system is B value. This measure of protein–protein interaction
erves as the ranking criteria for all additives in the screen, with DLS
nd DSC measurements acting as secondary quality control mea-
urements. Additives which increase B value are not necessarily the
ame as those which improve thermal stability. On the contrary,
here has not been a published direct correlation between thermal
tability and solubility or thermal stability and B value. These are
ndependent measurements and because the primary goal of the
creen is to identify a formulation with increased colloidal stability,
rior knowledge of thermal stability is not necessary or sufﬁcient
o identify improved solubility formulations.
.3. Incomplete factorial
The incomplete factorial screen design is based on experimen-
al results from the initial screen. Additives identiﬁed in the initial
creen (a different set for each protein) are combined using an
rthogonal array to ensure equal representation of each additive
hroughout the screen. Each formulation in the incomplete facto-
ial is evaluated by SIC to determine the B-value of the protein in
he formulation. Appendices 3 and 4 identify all additives in the
ncomplete factorial for the Minerva Fab. The formulations from
he incomplete factorial with the most positive B-values are listed
n Table 3.
.4. Neural network
Neural network training produced a Fab validation error 1.2 B
nits and a percent validation error of 12.4%. After training, predic-
ion of the complete factorial of additive combinations resulted in
oth positive and negative B-value predictions.
The range of B-values predicted for the Minerva protein was
5.4 to +4.3 B units. Even before empirical conﬁrmation, the broad
ange of these B-values included many formulations that weregr. B 971 (2014) 99–106 105
expected to have high solubility. Literature on the empirical rela-
tionship between B-values and solubility [11–13,33], shows that
protein solubility increases with B-value. The increase in solubil-
ity is nonlinear with respect to B-value with a more rapid increase
above zero. The solubility reported by Minerva (Fig. 3) conﬁrms
that the formulations with high positive predicted B-value have
improved solubility.
6. Conclusion
The results demonstrate a signiﬁcant improvement for the pre-
dicted formulations versus the original formulation with respect
to both increased B-values and increased protein solubility in the
top four predicted formulations. The approach utilizes our novel
technology (HSC) and design of experiments to evaluate multi-
ple tiers of additive formulations. The results from these screens
are evaluated with an artiﬁcial neural network model to identify
formulations with improved solubility behavior. The formulations
identiﬁed for the Minerva Fab improved solubility one-hundred
fold over the existing baseline formulation and enabled the pro-
tein to advance to animal trials using two  of the best predicted
formulations.
The novel contributions of this paper are three-fold. (1) The
addition of an initial screen to previous methodologies which
allows a large number of individual additives to be ranked with-
out a-priori knowledge of how those additives will affect B value
for a given protein. This was  demonstrated with the inclusion of
both expected (trehalose) and unexpected (LiCl) additives in the
incomplete factorial. (2) The use of DSC and DLS as quality control
methods in a larger multi-tiered screening process. This permits
the exclusion of false-positive B values due to protein denaturation
as well as the inclusion of a formulation. (3) Demonstration that the
ﬁrst two contributions enabled the identiﬁcation of a formulation
with a 100-fold increase in solubility for a pharmaceutical protein.
It is important to emphasize the incorporation of baseline checks
throughout the process. Differential scanning calorimetry is essen-
tial to exclude false positives. After the initial screen of formulation
additives, it is common to have at least one or two  additives which
reduce the unfolding temperature of the protein or result in dena-
turation, but result in positive B-values due to size exclusion effects.
One could argue that a reduction in unfolding temperature of 2–3 ◦C
is not signiﬁcant in the thermal stability of a protein—especially if
those temperatures are around 80 ◦C. However, a strong relation-
ship between unfolding temperature and biological protein activity
has not yet been evaluated for a signiﬁcant number of proteins. In
this screening process a cautious approach is taken to eliminate
additives which could alter activity due to a conformational change.
This is acceptable due to the large number of additives evaluated
and the small incremental cost due to additional protein consump-
tion. As more evidence is gathered regarding the nature of unfolding
temperatures, solubility and activity, operating procedures will be
adjusted. The evaluation presented in this paper provides a snap-
shot of a current screening technique to improve solubility behavior
of therapeutic proteins. An aspect of this research that must be
emphasized is that of solubility behavior vs absolute solubility.
Absolute maximum solubility is difﬁcult to measure for a protein
solution because of the ability of a protein to super-saturate and
result in signiﬁcantly different solubility maximums in slightly dif-
ferent formulation conditions. Therefore, one approach that may
prove useful is to evaluate the tendency of the protein to aggre-
gate at increasing concentrations. Laser light scattering (and an
observed A280 signal decrease) can be used to assess the tendency
of different formulations to produce increasing protein aggrega-
tion. This technique allows protein solubility assessment with a
small amount of protein. To our knowledge, a method does not
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xist (when only small quantities of puriﬁed protein are available)
o evaluate absolute protein solubility for proteins exhibiting a high
aximum solubility.
The improvement of Mab  solubility based on Fab screening
uggests that problematic protein domains could be formulated
eparately to improve solubility of the complete protein. This result
s supported by other work in our lab that involves determination
f solution conditions that improve the solubility of cystic ﬁbrosis
ransmembrane conductance regulator (CFTR) protein. Due to the
ifﬁculty in expressing a sufﬁcient amount of this integral mem-
rane protein to support self-interactions studies, one of CFTR’s
ucleotide binding domains (NBD1), was used to determine solu-
ion conditions that also improved solubility of the full-length
rotein [34]. Although there is insufﬁcient evidence to assume that
his might apply to all proteins that exhibit poor solubility, when a
peciﬁc domain is known to cause solubility problems (such as with
BD1 or a speciﬁc Fab) solubility improvements of the domain is a
alid starting point.
An alternative method to improve solubility is mutagenesis of
peciﬁc amino acids. This technique was successfully utilized by
ethea et al. and protein–protein attraction was  evaluated pri-
arily with the use of cross-interaction chromatography [35]—an
dentical technique to self-interaction chromatography with the
xception that the mobile phase and stationary phase consist of
ifferent molecules (Fab and Mab) [36]. In the Bethea publica-
ion Fab and Mab  were both shown to have signiﬁcantly negative
 values, although the Fab did not display a population of dif-
erent size aggregates due to postulated formation of stable and
omogeneous tetramers. Conditions that reduced the interac-
ion/attraction between the Fab and the Mab  were demonstrated to
lso reduce Mab–Mab interactions. As the protein–protein interac-
ion is detectable in both the Mab  and Fab fragments it is expected
hat the formulation screening technique presented here (per-
ormed using self-interactions for one domain of a protein) could be
sed to identify additives which reduce Fab protein–protein inter-
ctions, conditions that may  also reduce Mab–Mab interactions.
As a method to enhance comprehensive formulation screens
multiple tiers of additives and an associated hardware) the HSC
ystem could beneﬁt from improvements that would reduce pro-
ein consumption and experiment time. Improvements to each step
n the evaluation process can potentially reduce protein use and
ime. In addition to efﬁciency (time and protein) optimizations, we
re exploring expansion of applications. For example an additional
mprovement would include use of circular dichroism as a reference
o ensure that the protein structure is not signiﬁcantly changing.
his would be beneﬁcial for therapeutic proteins at the pre-clinical
tage in which end point results are undergoing additional analyt-
cal evaluations (e.g. the Minerva Fab).
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